Suppression of human eosinophil respiratory burst and cyclic AMP hydrolysis by inhibitors of type IV phosphodiesterase: interaction with the beta adrenoceptor agonist albuterol

G Dent, MA Giembycz, PM Evans, KF Rabe and PJ Barnes

Department of Thoracic Medicine, Royal Brompton, National Heart and Lung Institute, London, United Kingdom.

The cyclic AMP phosphodiesterase (PDE) III/IV inhibitor, zardaverine, and the PDE IV-selective inhibitor, rolipram, both caused concentration- dependent inhibition of opsonized zymosan-stimulated superoxide anion generation by purified human peripheral blood eosinophils with approximate IC50 values of 30 and 40 microM, respectively. In contrast, the selective PDE III inhibitor, SK&F 94120, was ineffective in suppressing this functional response at concentrations below 100 microM. The inhibitory effects of rolipram and zardaverine on superoxide anion generation were increased in the presence of the beta- 2 adrenoceptor agonist, albuterol, which itself was an inhibitor of eosinophil respiratory burst (IC50 = 20 microM). The effects of albuterol and the PDE inhibitors in combination were simply additive. Paradoxically, both rolipram and zardaverine significantly potentiated albuterol-induced cyclic AMP accumulation in a synergic fashion. Cyclic AMP PDE activity of eosinophil homogenates was inhibited by both zardaverine (IC50 = 515 nM) and rolipram (IC50 = 550 nM) as well as two other PDE IV-selective inhibitors, Ro 20-1724 (IC50 = 3.0 microM) and denbufylline (IC50 = 360 nM), whereas SK&F 94120 was ineffective. These data suggest that cyclic AMP levels in human eosinophils are regulated by the action of a type IV PDE isoenzyme and that elevation of the intracellular cyclic AMP concentration by PDE IV inhibition can suppress the functional activity of these cells. However, the suppressor effect of the PDE IV inhibitors appears to be independent of that of a beta-2 adrenoceptor agonist, implying a possible adenylyl cyclase-independent mechanism of action for beta agonists in eosinophils.

Volume 271, Issue 3, pp. 1167-1174, 12/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				M. Singh and H. K. Saini Resident Cardiac Mast Cells and Ischemia-Reperfusion Injury Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2003; 8(2): 135 - 148. [Abstract] [PDF]

				N. J. Thomas, J. A. Carcillo, W. A. Herzer, Z. Mi, and E. K. Jackson Chronic Type IV Phosphodiesterase Inhibition Protects Glomerular Filtration Rate and Renal and Mesenteric Blood Flow in a Zymosan-Induced Model of Multiple Organ Dysfunction Syndrome Treated with Norepinephrine J. Pharmacol. Exp. Ther., January 1, 2001; 296(1): 168 - 174. [Abstract] [Full Text]

				T. Ikemura, J. Schwarze, M. Makela, A. Kanehiro, A. Joetham, K. Ohmori, and E. W. Gelfand Type 4 Phosphodiesterase Inhibitors Attenuate Respiratory Syncytial Virus-Induced Airway Hyper-Responsiveness and Lung Eosinophilia J. Pharmacol. Exp. Ther., August 1, 2000; 294(2): 701 - 706. [Abstract] [Full Text]

				M. A. Giembycz and M. A. Lindsay Pharmacology of the Eosinophil Pharmacol. Rev., June 1, 1999; 51(2): 213 - 340. [Abstract] [Full Text] [PDF]

				K. Fujii, H. Kohrogi, H. Iwagoe, J. Hamamoto, N. Hirata, E. Goto, O. Kawano, K. Wada, S. Yamagata, and M. Ando Novel Phosphodiesterase 4 Inhibitor T-440 Reverses and Prevents Human Bronchial Contraction Induced by Allergen J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 162 - 169. [Abstract] [Full Text]

				B. de Andres, E. Rakasz, M. Hagen, M. L. McCormik, A. L. Mueller, D. Elliot, A. Metwali, M. Sandor, B. E. Britigan, J. V. Weinstock, et al. Lack of Fc-epsilon Receptors on Murine Eosinophils: Implications for the Functional Significance of Elevated IgE and Eosinophils in Parasitic Infections Blood, May 15, 1997; 89(10): 3826 - 3836. [Abstract] [Full Text] [PDF]

				T. J. TORPHY Phosphodiesterase Isozymes . Molecular Targets for Novel Antiasthma Agents Am. J. Respir. Crit. Care Med., February 1, 1997; 157(2): 351 - 370. [Full Text]